Loading...

General Moly, Inc.

GMO.TOTSX
Basic Materials
Other Precious Metals
$0.04
$0.00(0.00%)
Canadian Market is Open • 11:59

General Moly, Inc. Fundamental Analysis

General Moly, Inc. (GMO.TO) shows weak financial fundamentals with a PE ratio of -0.47, profit margin of 0.00%, and ROE of -8.88%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position83.11%
PEG Ratio0.00

Areas of Concern

ROE-8.88%
Operating Margin0.00%
Current Ratio0.14
We analyze GMO.TO's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 13.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
13.7/100

We analyze GMO.TO's fundamental strength across five key dimensions:

Efficiency Score

Weak

GMO.TO struggles to generate sufficient returns from assets.

ROA > 10%
-2.53%

Valuation Score

Excellent

GMO.TO trades at attractive valuation levels.

PE < 25
-0.47
PEG Ratio < 2
0.00

Growth Score

Weak

GMO.TO faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Moderate

GMO.TO shows balanced financial health with some risks.

Debt/Equity < 1
0.08
Current Ratio > 1
0.14

Profitability Score

Weak

GMO.TO struggles to sustain strong margins.

ROE > 15%
-888.15%
Net Margin ≥ 15%
0.00%
Positive Free Cash Flow
No

Key Financial Metrics

Is GMO.TO Expensive or Cheap?

P/E Ratio

GMO.TO trades at -0.47 times earnings. This suggests potential undervaluation.

-0.47

PEG Ratio

When adjusting for growth, GMO.TO's PEG of 0.00 indicates potential undervaluation.

0.00

Price to Book

The market values General Moly, Inc. at 0.04 times its book value. This may indicate undervaluation.

0.04

EV/EBITDA

Enterprise value stands at -0.26 times EBITDA. This is generally considered low.

-0.26

How Well Does GMO.TO Make Money?

Net Profit Margin

For every $100 in sales, General Moly, Inc. keeps $0.00 as profit after all expenses.

0.00%

Operating Margin

Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.

0.00%

ROE

Management delivers $-8.88 in profit for every $100 of shareholder equity.

-8.88%

ROA

General Moly, Inc. generates $-2.53 in profit for every $100 in assets, demonstrating efficient asset deployment.

-2.53%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $-0.04 in free cash annually.

$-0.04

FCF Yield

GMO.TO converts -1.40% of its market value into free cash.

-1.40%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.47

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.00

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.04

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.08

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.14

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.09

vs 25 benchmark

ROA

Return on assets percentage

-0.03

vs 25 benchmark

ROCE

Return on capital employed

-0.02

vs 25 benchmark

How GMO.TO Stacks Against Its Sector Peers

MetricGMO.TO ValueSector AveragePerformance
P/E Ratio-0.4723.95 Better (Cheaper)
ROE-8.88%903.00% Weak
Net Margin0.00%-108951.00% (disorted) Weak
Debt/Equity0.080.54 Strong (Low Leverage)
Current Ratio0.146.83 Weak Liquidity
ROA-2.53%-10157.00% (disorted) Weak

GMO.TO outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews General Moly, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Cyclical, Commodity, Value

EPS CAGR

N/A

Industry Style: Cyclical, Commodity, Value

FCF CAGR

N/A

Industry Style: Cyclical, Commodity, Value

Fundamental Analysis FAQ